Trial Profile
A Randomised, Open-label Phase III Trial Evaluating the Addition of Denosumab to Standard First-line Anticancer Treatment in Advanced NSCLC
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms SPLENDOUR
- 01 Jan 2023 Results from SPLENDOUR and other study evaluating the clinical significance of RANK/L expression in NSCLC , published in the Lung Cancer
- 01 Nov 2021 Results (n=740) of pooled analysis from SPLENDOUR and AMGEN-249; assessing potential anti-tumour effect and subsequent OS impact of denosumab in NSCLC and assessing efficacy in term of OS and progression-free survival in the combined data sets, published in the Lung Cancer
- 07 May 2021 This trial has been completed in Slovenia according to European Clinical Trials Database record.